Lv4
624 积分 2025-09-15 加入
The Landscape of Clinical Trials for Claudin18.2-Positive Gastric Cancer
12天前
已完结
Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)
12天前
已完结
Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
12天前
已完结
低位直肠癌术前多学科整合临床决策中国专家共识
13天前
已完结
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma
26天前
已完结
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
1个月前
已完结
Chemoimmunotherapy in Deficient DNA Mismatch Repair Metastatic Colorectal Cancer: What COMMIT Can and Cannot Tell Us
1个月前
已关闭
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2个月前
已完结
PI3K/AKT通路的激活促进HER2阳性胃癌曲妥珠单抗的耐药
2个月前
已完结
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
